Replies to post #3953 on GTC Biotherapeutics (fka GTCB)

[kris_kade]

Artisan Pharma might be ahead of GTCB on DIC indications where the real revenue is....

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

This study is not yet open for patient recruitment.
Verified by Artisan Pharma, Inc. June 2007

Sponsored by: Artisan Pharma, Inc.
Information provided by: Artisan Pharma, Inc.
ClinicalTrials.gov Identifier: NCT00487656


Purpose

The purpose of this study is to see if ART-123 (recombinant human soluble thrombomodulin) decreases the number of people who die as a result of Disseminated Intravascular Coagulation (DIC) complication of sepsis.
Condition Intervention Phase
Sepsis
Disseminated Intravascular Coagulation
Drug: ART-123 (recombinant human soluble thrombomodulin)
Phase II


MedlinePlus related topics: Bleeding Disorders; Blood and Blood Disorders; Sepsis
Genetics Home Reference related topics: Bleeding Disorders; Blood and Blood Disorders

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Number of arms in study: 2

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation

Further study details as provided by Artisan Pharma, Inc.:
Primary Outcome Measures:

[tarado96]

Atryn ready to launch, and the fud patrol is working on both boards. What a coincidence!